BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 34208157)

  • 1. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
    Lee HW
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
    Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
    Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global management of brain metastasis from renal cell carcinoma.
    Pierrard J; Tison T; Grisay G; Seront E
    Crit Rev Oncol Hematol; 2022 Mar; 171():103600. PubMed ID: 35063636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors.
    Incorvaia L; Madonia G; Corsini LR; Cucinella A; Brando C; Gagliardo C; Santoni M; Fanale D; Inno A; Fazio I; Foti G; Galia M; Badalamenti G; Bazan V; Russo A; Gori S
    Crit Rev Oncol Hematol; 2021 Jul; 163():103390. PubMed ID: 34090998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
    Parmar A; Soliman H; Sahgal A; Bjarnason GA
    Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases.
    Steindl A; Alpar D; Heller G; Mair MJ; Gatterbauer B; Dieckmann K; Widhalm G; Hainfellner JA; Schmidinger M; Bock C; Müllauer L; Preusser M; Berghoff AS
    ESMO Open; 2021 Apr; 6(2):100057. PubMed ID: 33588158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
    Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
    Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma.
    Su J; Zhou L; Zhang Z; Xiao X; Qin Y; Zhou X; Huang T
    Front Immunol; 2023; 14():1146738. PubMed ID: 37350955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study.
    Internò V; Massari F; Rudà R; Maiorano BA; Caffo O; Procopio G; Bracarda S; Atzori F; Passarelli A; Bersanelli M; Stellato M; Fornarini G; Galli L; Ortega C; Zanardi E; Incorvaia L; Facchini G; Giron Berrios JR; Ricotta R; Santoni M; Funaioli C; Trerotoli P; Porta C; Rizzo M
    ESMO Open; 2023 Aug; 8(4):101598. PubMed ID: 37467658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
    Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
    Front Immunol; 2022; 13():980456. PubMed ID: 36238308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
    Sperduto PW; Deegan BJ; Li J; Jethwa KR; Brown PD; Lockney N; Beal K; Rana NG; Attia A; Tseng CL; Sahgal A; Shanley R; Sperduto WA; Lou E; Zahra A; Buatti JM; Yu JB; Chiang V; Molitoris JK; Masucci L; Roberge D; Shi DD; Shih HA; Olson A; Kirkpatrick JP; Braunstein S; Sneed P; Mehta MP
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):845-853. PubMed ID: 29976497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
    Huntoon K; Damante M; Wang J; Olencki T; Elder JB
    Curr Probl Cancer; 2022 Apr; 46(2):100805. PubMed ID: 34836657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
    Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.
    Sun M; De Velasco G; Brastianos PK; Aizer AA; Martin A; Moreira R; Nguyen PL; Trinh QD; Choueiri TK
    Eur Urol Focus; 2019 May; 5(3):474-481. PubMed ID: 29311016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
    Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
    J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
    Han SC; Yin HQ; Xu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.